Analyst: Unexpected Novo upgrade "demonstrates positive development"
Novo Nordisk's Friday upgrade to its financial guidance surprised analysts at Sydbank, who see it as an expression of strong growth momentum for the company's GLP and obesity business.
by marketwire, translated by catherine brett
After a quarter of taking market shares with diabetes drug Ozempic and increased sales of GLP-1 analog and obesity treatments, Novo Nordisk upgraded its full-year financial guidance on Friday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk upgrades guidance
For subscribers
US-based obesity firm hires former Novo VP
For subscribers
.jpg)
.jpg&w=384&q=75)
